{
    "id": 32625,
    "fullName": "NUP214 - ABL1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "NUP214-ABL1 results from the fusion of NUP214 and ABL1, which leads to constitutive kinase activity and transformation of cells in culture (PMID: 18784740, PMID: 18614052). NUP214-ABL1 has been identified in T-cell acute lymphoblastic leukemia (PMID: 18401417, PMID: 15361874).",
            "references": [
                {
                    "id": 17913,
                    "pubMedId": 18614052,
                    "title": "Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18614052"
                },
                {
                    "id": 17910,
                    "pubMedId": 18401417,
                    "title": "Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18401417"
                },
                {
                    "id": 17911,
                    "pubMedId": 15361874,
                    "title": "Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15361874"
                },
                {
                    "id": 17912,
                    "pubMedId": 18784740,
                    "title": "Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18784740"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8021,
        "geneSymbol": "NUP214",
        "terms": [
            "NUP214",
            "CAIN",
            "CAN",
            "IIAE9"
        ]
    },
    "variant": "NUP214 - ABL1",
    "createDate": "02/20/2020",
    "updateDate": "02/21/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 25,
                "geneSymbol": "ABL1",
                "terms": [
                    "ABL1",
                    "ABL",
                    "BCR-ABL",
                    "bcr/abl",
                    "c-ABL",
                    "c-ABL1",
                    "CHDSKM",
                    "JTK7",
                    "p150",
                    "v-abl"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 20518,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) and GSK690693 combination treatment enhanced inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9391,
                "therapyName": "GSK690693 + Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20519,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HQP1351 and GSK690693 combination treatment enhanced inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9396,
                "therapyName": "GSK690693 + HQP1351",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20517,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) and GSK690693 combination treatment enhanced inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9387,
                "therapyName": "GSK690693 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20522,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HQP1351 and ZSTK474 combination treatment enhanced inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9395,
                "therapyName": "HQP1351 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20516,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HQP1351 and Torin 2 combination treatment resulted in enhanced cell cycle arrest, autophagy, apoptosis and inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9393,
                "therapyName": "HQP1351 + Torin 2",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20514,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) and Torin 2 combination treatment resulted in enhanced cell cycle arrest, autophagy, apoptosis and inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9386,
                "therapyName": "Imatinib + Torin 2",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20508,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) treatment inhibited phosphorylation of Crkl and reduced viability of T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20515,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) and Torin 2 combination treatment resulted in enhanced cell cycle arrest, autophagy, apoptosis and inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9389,
                "therapyName": "Nilotinib + Torin 2",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) treatment inhibited phosphorylation of Crkl and reduced viability of T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20513,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HQP1351 and BGT226 combination treatment resulted in enhanced cell cycle arrest, autophagy, apoptosis and inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9394,
                "therapyName": "BGT226 + HQP1351",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20512,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) and BGT226 combination treatment resulted in enhanced cell cycle arrest, autophagy, apoptosis and inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9390,
                "therapyName": "BGT226 + Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) and BGT226 combination treatment resulted in enhanced cell cycle arrest, autophagy, apoptosis and inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9385,
                "therapyName": "BGT226 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20521,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) and ZSTK474 combination treatment enhanced inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9392,
                "therapyName": "Nilotinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HQP1351 treatment inhibited phosphorylation of Crkl and reduced viability of T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 8237,
                "therapyName": "HQP1351",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20520,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) and ZSTK474 combination treatment enhanced inhibition of viability in T-cell acute lymphoblastic leukemia cell lines harboring NUP214-ABL1 fusion in culture (PMID: 27821800).",
            "molecularProfile": {
                "id": 35215,
                "profileName": "NUP214 - ABL1"
            },
            "therapy": {
                "id": 9388,
                "therapyName": "Imatinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17818,
                    "pubMedId": 27821800,
                    "title": "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35215,
            "profileName": "NUP214 - ABL1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}